<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121069</url>
  </required_header>
  <id_info>
    <org_study_id>3990-02-9</org_study_id>
    <nct_id>NCT00121069</nct_id>
  </id_info>
  <brief_title>Study of Escitalopram in the Treatment of Specific Phobia</brief_title>
  <official_title>Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Connor, Kathryn M., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Connor, Kathryn M., M.D.</source>
  <brief_summary>
    <textblock>
      This pilot study is designed to assess the efficacy of escitalopram in the treatment of
      specific phobia in adult outpatients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of
      12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult
      outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of
      specific phobia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date>September 2004</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response based on CGI-I category</measure>
  </secondary_outcome>
  <enrollment>12</enrollment>
  <condition>Phobic Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18-65 years of age

          -  DSM-IV criteria for specific phobia according to the MINI

          -  For women of childbearing potential, a negative serum pregnancy test at screening

          -  Written informed consent

        Exclusion Criteria:

          -  Any current primary DSM-IV diagnosis other than specific phobia

          -  History of DSM-IV substance abuse or dependence within the last months

          -  Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder,
             mental retardation, or other pervasive developmental disorder or cognitive disorder
             due to a general medical condition

          -  Suicide risk or serious suicide attempt within the last year

          -  Clinically significant laboratory or EKG abnormality or unstable medical condition

          -  For women of childbearing potential, unwillingness to use an acceptable form of
             contraception during the study

          -  Subjects needing concurrent use of psychotropic medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn M. Connor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>July 19, 2005</last_update_submitted>
  <last_update_submitted_qc>July 19, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2005</last_update_posted>
  <keyword>specific phobia</keyword>
  <keyword>anxiety</keyword>
  <keyword>SSRI</keyword>
  <keyword>clinical trial</keyword>
  <keyword>escitalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

